Transcatheter aortic valve implantation: the shape matters

Transcatheter aortic valve implantation (TAVI) has brought about a paradigm change in the treatment of patients with severe aortic stenosis. There is a growing body of evidence and continuous advancement in the field of transcatheter valve intervention, including expansion to indications other than aortic stenosis, such as pure aortic regurgitation (AR). Currently, the only device approved for transcatheter treatment of pure AR is the Trilogy valve (JenaValve). However, logistical issues and strict anatomical requirements impede its unrestricted use, which is why alternative valve systems must be considered for this subset of patients. Overall, the results of TAVI for ...